SEC Form 3 · accession 0001493152-17-002589
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carlos Fernando Alaman Volnie
Officer — Chief Operating Officer-Vitel · 10% Owner
Period of report
Mar 10, 2017
Accepted (ET)
Mar 20, 2017 · 6:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 30,579,006 | I | Beneficiary | |
| Series B Preferred StockF1 | holding | — | — | — | 2,500,000 | I | Beneficiary |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares are owned by Banco Actinver, S.A., in its capacity as Trustee of the Irrevocable Management Trust Agreement Trust No. 2868 and reflects the Issuer's shares beneficially owned by the reporting person.